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Objectives: To examine the relationship between antidepressant use in pregnancy and low birth weight (LBW)
and preterm birth (PTB).
Data Sources and Study Selection:We searched English and non-English language articles via PubMed, CINAHL
and PsychINFO (from their start dates through December 1st, 2012). We used the following keywords and
their combinations: antidepressant, selective serotonin reuptake inhibitor (SSRI), pregnancy, antenatal, prenatal,
birthweight, birth weight, preterm, prematurity, gestational age, fetal growth restriction, intrauterine growth
restriction, and small-for-gestational age. Published studies were considered eligible if they examined exposure
to antidepressant medication use during pregnancy and reported data on at least one birth outcome of
interest: PTB (b37 weeks gestation) or LBW (b2500 g). Of the 222 reviewed studies, 28 published studies met
the selection criteria.
Data Extraction: Two authors independently extracted study characteristics from eligible studies.
Results: Using random-effects models, antidepressant use in pregnancy was signiﬁcantly associated with LBW
(RR: 1.44, 95% conﬁdence interval (CI): 1.21-1.70) and PTB (RR: 1.69, 95% CI: 1.52-1.88). Studies varied widely
in design, populations, control groups and methods. There was a high level of heterogeneity as measured by
I2 statistics for both outcomes examined. The relationship between antidepressant exposure in pregnancy and
adverse birth outcomes did not differ signiﬁcantly when taking into account drug type (SSRI vs. other ormixed)
or study design (prospective vs. retrospective). There was a signiﬁcant association between antidepressant
exposure and PTB for different types of control status used (depressed, mixed or nondepressed).
Conclusions: Antidepressant use during pregnancy signiﬁcantly increases the risk for LBW and PTB.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Depression is a prevalent condition in pregnancy affecting up to 13%
of women [1]. Untreated antenatal depression is associated with poor
self-care during pregnancy, risk of postpartum depression, risk of
impairedmaternal–infant attachmentanddelays in infant development
when it persists into the postpartum period [2,3]. Available treatmentsthe following grant from the
principal investigator: Wayne
an, Bridge, and Katon have no
oses royalties from Up-To-Date.
or her thoughtful review of the
+1 617 665 2521.
).
-NC-ND license.for depressive disorders include psychotherapeutic interventions and
antidepressant medications such as selective serotonin inhibitors
(SSRIs) and tricyclic antidepressants. Although psychotherapy may be
a reasonable treatment option for mild to moderate depression,
antidepressants are often required for the effective treatment of severe
maternal depression [4,5]. Recent estimates of antidepressant exposure
among pregnant women range from 3% to 13% [6,7].
Preterm birth (PTB) and low birth weight (LBW) occur at national
rates of 12.2% and 8.2%, respectively [8]. Several studies over the past
two decades have attempted to characterize the relationship between
antidepressant use in pregnancy and risk of adverse birth outcomes
[9]. However, in general, the observational studies published to date
have provided inconsistent and sometimes conﬂicting ﬁndings on the
relationship between antidepressant exposure and LBW and PTB.
Differences in study design (prospective and retrospective), patient
populations (patients recruited from mental health settings and
14 H. Huang et al. / General Hospital Psychiatry 36 (2014) 13–18patients identiﬁed from registries), comparator groups (nonde-
pressed or depressed controls) and sample sizes make it difﬁcult to
interpret the variability of ﬁndings. Many studies are also limited in
their ability to adequately control for important potential confound-
ing variables such as smoking, substance abuse, medical conditions
(such as pregnancy-induced hypertension and gestation diabetes)
and depression severity — all of which have been found to be
independently associated with adverse birth outcomes [10,11].
A recent meta-analysis has shown that although antidepressant
use in pregnancy was not associated with spontaneous abortion,
exposure was signiﬁcantly associated with both preterm delivery and
LBW [12]. The goal of this meta-analysis is to add to the literature by
further examining this association (e.g., reproductive outcomes of
depressed women who are treated with antidepressants of any type
during pregnancy), adding eight studies published after June 2010
(the end of the above systematic review). We also examine how the
quality and study design of these previous studies inﬂuence the
outcomes reported in this meta-analysis via sensitivity analyses.
2. Methods
2.1. Search strategy for identiﬁcation of studies
We searched for English and non-English language articles via
MEDLINE, CINAHL, PyschINFO and reference lists of review papers.
The electronic search included studies from the respectively data-
bases' start dates and ended on December 1, 2012. We used the
following keywords and their combinations: antidepressant, selective
serotonin reuptake inhibitor, SSRI, pregnancy, antenatal, prenatal,
birthweight, birth weight, preterm, prematurity, gestational age, fetal
growth restriction, intrauterine growth restriction and small-for-
gestational age. Published English-language and non-English language
studies were included in this meta-analysis if they provided the
relative risk (RR) or adequate data for the calculation of an effect size
as an odds ratio (OR) between antidepressant use and an adverse
birth outcome (i.e., LBW or PTB). Included studies could be eitherTable 1
Characteristics of studies included in the meta-analysis
Trial Year Exposure Controls Trial design Sa
siz
Grzeskowiak [14] 2012 SSRI Depressed Retrospective
El Marroun [15] 2012 SSRI Nondepressed Prospective
Klieger-Grossmann [16] 2012 Escitalopram Nondepressed Prospective
Nordeng [17] 2012 Various AD Mixed Prospective
Yonkers [18] 2012 SSRI Nondepressed Prospective
Colvin [19] 2011 SSRI Nondepressed Retrospective
Latendresse [20] 2011 SSRI Mixed Retrospective
Roca [21] 2011 SSRI Nondepressed Retrospective
Einarson [22] 2010 Various AD Nondepressed Retrospective
Lewis [23] 2010 SSRI or SNRI Mixed Prospective
Reis [24] 2010 SSRI Mixed Retrospective 10
Lund [25] 2009 SSRI Nondepressed Prospective
Toh [26] 2009 SSRI Mixed Retrospective
Wisner [27] 2009 SSRI Nondepressed Prospective
Maschi [28] 2008 Various AD Mixed Prospective
Davis [29] 2007 SSRI Mixed Retrospective
Lennestal [30] 2007 SNRI Mixed Retrospective 8
Pearson [31] 2007 Various AD Nondepressed Retrospective
Suri [32] 2007 Various AD Depressed Prospective
Djulus [33] 2006 Mirtazapine Nondepressed Prospective
Wen [34] 2006 SSRI Mixed Retrospective
Sivojelezova [35] 2005 Citalopram Nondepressed Prospective
Kallen [36] 2004 Various AD Mixed Prospective 5
Casper [37] 2003 SSRI Depressed Prospective
Simon [38] 2002 SSRI Depressed Retrospective
Ericson [39] 1999 Various AD Mixed Retrospective 2
Chambers [40] 1996 Fluoxetine Nondepressed Prospective
Pastuszak [41] 1993 Fluoxetine Nondepressed Prospective
AD, antidepressants; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin and noreprospective or retrospective. Studies were excluded if they lacked the
outcomes of interest. Authors H.H. and S.C. contacted authors of
studies that reported outcomes of interest as continuous variables for
information to calculate effect sizes as ORs.
2.2. Data extraction
2.2.1. Adverse birth outcomes
Two authors (H.H. and S.C.) reviewed all studies. A standardized
eligibility and quality of study coding sheet were designed a priori
[13]. Of the 222 published studies reviewed, 28 met the inclusion
criteria. Fifteen studies on LBW (b2500 g) and 28 studies on PTB (b37
weeks gestational age) were included in this meta-analysis (Table 1).
2.2.2. Methodologic quality assessment
H.H. and S.C. rated each of the studies independently and assigned a
quality score to each of the studies selected for this meta-analysis
according to guidelines described by Downs and Black [42]. We used a
consensus approachand resolveddifferences in scoringprior to assigning
a ﬁnal quality score. The quality measure was based on the following
indicators: whether characteristics of patients were clearly described,
whether measures of antidepressant exposure were reliable and valid,
the degree of adjustment formultiple potential confounding variables in
analyses, whethermeasurement and adjustment for depression severity
was made, the study representativeness of the potential population and
sample size. The total quality scores ranged from 0 to 13.
2.2.3. Analysis
The association between antidepressant exposure in the antenatal
period and adverse birth outcomewas examined using RRs. To do this,
we considered ORs as surrogates for RRs because when outcomes
undergoing study are relatively uncommon, the relative odds
approximate RRs [2]. Each study's RR was weighted according to the
inverse of its variance using random-effects models in order to
calculate a pooled RR. Ninety-ﬁve percent conﬁdence intervals (95%
CIs) were calculated for each study result and for the pooledmple
e
RR (95% CI) LBW RR (95% CI) PTB Quality
Score
Controlled for
depression severity
1787 2.26 (1.31–3.91) 2.68 (1.83–3.93) 8 No
7126 1.65 (0.77–3.56) 2.14 (1.08–4.25) 9 No
425 4.51 (1.43–18.69) 2.21 (0.92–5.68) 7 No
62204 0.62 (0.33–1.16) 1.21 (0.87–1.69) 11 Yes
2432 1.62 (1–2.5) 9 Yes
96698 1.4 (1.25–1.56) 1.43 (1.24–1.65) 8 No
100 11.7 (2.2–60.7) 7 Yes
252 1.37 (0.46–3.81) 3.44 (1.30–9.11) 7 No
1856 1.7 (1.18–2.45) 6 No
54 8.33 (1.11–62.67) 4.52 (0.47–43.41) 9 Yes
68177 1.13 (0.97–1.31) 1.45 (1.31–1.63) 6 No
52099 0.63 (0.15–2.67) 2.02 (1.29–3.16) 7 No
5796 1.27 (0.59–2.76) 8 No
179 5.43 (1.98–14.84) 9 No
1400 1.18 (0.53–2.41) 2.31 (1.14–4.63) 3 No
50710 1.45 (1.25–1.68) 3 No
60215 1.12 (0.74–1.68) 1.6 (1.19–2.15) 8 No
252 1.07 (0.4–2.67) 4 No
71 3.5 (0.4–165.11) 11 Yes
208 5.43 (1.11–51.83) 7 No
4850 1.58 (1.19–2.11) 1.57 (1.28–1.92) 7 No
264 2.31 (0.71–8.71) 6 No
63656 1.98 (1.55–2.52) 1.96 (1.60–2.41) 9 No
44 0.4 (0.005–33.99) 11 Yes
370 2.73 (0.92–8.09) 4.38 (1.57–12.22) 8 No
81728 1.32 (0.96–1.80) 1.43 (1.14–1.8) 4, 6 No
290 2.65 (0.98–6.89) 3 No
256 0.85 (0.22–3.09) 2 No
pinephrine reuptake inhibitors.
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Fig. 1. Identiﬁcation of independent studies for inclusion in the meta-analysis (from PRISMA ﬂow diagram guidelines).
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Meta-analysis version 2.2 (Biostat, Englewood, NJ).
Heterogeneity of effect size was assessed using the Cochran Qχ2
statistic (P≤ .10) and the I2 statistic, which indicates the percentage of
variation in the effect size estimate attributable to heterogeneity
rather than sampling error [43]. Random-effects models were used in
all analyses because the Q statistic and the I2 statistic indicated
substantial heterogeneity of effect size in the primary analyses
examining the association between antidepressant exposure and
each adverse birth outcome. Random-effects meta-regression ana-Table 2
Effect of antenatal antidepressant exposure on outcomes of LBW and PTB
Outcome No. of
studies
RRa % (95% CI) P value Heterogeneity
Qdf
within
P value % Variance
explained
LBW 15 1.44 (1.21–1.70) b .001 37.114 .001 62
PTB 28 1.69 (1.52–1.88) b .001 49.427 .005 45
Abbreviations: No. indicates number; df, degrees of freedom.
a Pooled effect size estimated using the random-effects model.lyses and moderator analyses were conducted to determine whether
four study characteristics could explain variability across studies: (a)
methodological quality of studies; (b) drug type (SSRI vs. other or
mixed); (c) control status (depressed, mixed or nondepressed); and
(d) study design (prospective vs. retrospective). “Leave-one-out”
analyses were conducted by iteratively deleting each study and
calculating the resulting effect size [44].
Publication bias was assessed visually using a funnel plot and
quantitatively using a regression procedure to measure funnel plot
asymmetry [45]. The trim-and-ﬁll method by Duval and Tweedie
[46,47] was used to adjust for potential publication bias. This method
assesses asymmetry in the funnel plot, imputes the number of
suspected missing studies and recalculates the adjusted pooled effect
size estimate. The adjusted result can be used as a sensitivity analysis
to indicate the extent to which publication bias may affect the pooled
estimate [2,48].
3. Results
The retrieval and selection strategy is shown in Fig. 1. Of the 222
citations found to meet the initial search criteria, 52 full-text articles
Table 4
Comparison of unadjusted pooled RRs and trim-and-ﬁll adjusted pooled RRs
Control group No. of
studies
Unadjusted pooled
RR (95% CI)a
Number
of missing
studies
Trim-and-ﬁll
adjusted pooled
RR (95% CI)b
Overall 28 1.69 (1.52 to 1.88) 7 1.62 (1.44 to 1.82)
Depressed 4 2.85 (2.00 to 4.07) 0 2.85 (2.00 to 4.07)
Mixed 11 1.55 (1.40 to 1.73) 2 1.53 (1.36 to 1.74)
Nondepressed 13 1.84 (1.50 to 2.27) 4 1.63 (1.29 to 2.05)
a Using random effects models.
b Using random–random effects trim-and-ﬁll models.
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included in this analysis. Table 1 provides the characteristics of
these studies. Further information was requested from 12 authors
(of 16 studies) of whom 6 authors responded, with two of these
authors providing data allowing two additional studies to be
included in the meta-analysis.
3.1. Association between antidepressant use in pregnancy and adverse
birth outcomes
3.1.1. LBW
Fifteen studies evaluated the association between antenatal
antidepressant use and LBW with RRs ranging from 0.62 to 8.33
(Table 2). Using the random-effects model, antenatal antidepressant
exposure was signiﬁcantly associated with LBW (RR=1.44, 95% CI:
1.21–1.70). Nine of the studies found no signiﬁcant association.
Signiﬁcant heterogeneity across studies was noted (Q14=37.1; P=
.001; I2=62%).
3.1.2. PTB
Twenty-eight studies evaluated the association between antenatal
antidepressant exposure and PTB with RRs ranging from 0.40 to 11.70
(Table 2). Using the random-effects model, antenatal antidepressant
exposure was signiﬁcantly associated with PTB (RR: 1.69, 95% CI:
1.52–1.88). Nine of the studies found no signiﬁcant association.
Signiﬁcant heterogeneity across studies was noted (Q27=49.4; P=
.005; I2=45%).
3.1.3. Moderators of outcome
Moderator analyses were conducted to explore sources of
heterogeneity (Table 3). In LBW studies, although the omnibus test
was not statistically signiﬁcant, studies that used a depressed controlTable 3
Moderators of effect of antidepressant exposure on outcomes of LBW and PTB
Moderator No. of
studies
Within group
RRa % (95% CI) P value H
Q
w
LBW
Drug type
SSRIs 9 1.48 (1.22–1.79) b .001 1
Other/Mixed antidepressants 6 1.31 (0.90–1.90) .16 1
Study design
Retrospective 8 1.36 (1.18–1.57) b .001 1
Prospective 7 1.54 (0.92–2.58) .10 1
Control groupb
Depressed 2 2.35 (1.44–3.83) .001
Mixed 8 1.32 (1.03–1.68) .03 2
Nondepressed 5 1.53 (1.06–2.20) .02
Control for depression severity
Yes 2 1.89 (0.15–23.5) .62
No 13 1.47 (1.26–1.72) b .001 2
PTB
Drug type
SSRIs 18 1.74 (1.52–2.00) b .001 3
Other/Mixed antidepressants 10 1.63 (1.38–1.93) b .001 1
Study design
Retrospective 13 1.59 (1.42–1.78) b .001 2
Prospective 15 1.91 (1.57–2.32) b .001 1
Control groupc
Depressed 4 2.85 (2.00–4.07) b .001
Mixed 11 1.55 (1.39–1.73) b .001 1
Nondepressed 13 1.84 (1.50–2.27) b .001 1
Control for depression severity
Yes 6 1.90 (1.07–3.38) .03 1
No 22 1.70 (1.53–1.89) b .001 3
a Pooled effect size estimated using the random-effects model.
b Pairwise effect of moderator: depressed versus mixed, Q1=4.3, P=.04; depressed vers
c Pairwise effect of moderator: depressed versus mixed, Q1=10.4, P=.001; depressed vegroup without antidepressant exposure yielded larger pooled RRs
than studies that used mixed controls (Q1=4.30, P=.038). Similarly,
PTB studies that used a depressed control group without antidepres-
sant exposure yielded larger RRs than studies that used either mixed
controls (Q1=10.45, P=.001) or nondepressed controls (Q1=4.35,
P=.037). In PTB studies, heterogeneity among studies was reduced by
the addition of the control group moderator (depressed: Q3=2.01;
P=.57; I2=0%; mixed: Q10=17.42; P=.07; I2=43%; nondepressed:
Q2=18.17; P=.11; I2=34%). Drug type, study design, control for
depression severity and study quality were not signiﬁcant moderators
of LBW or PTB.
3.1.4. Leave-one-out analyses
Sensitivity analyses revealed that no single study unduly inﬂu-
enced the pool risk ratio estimates of the association between
antenatal antidepressant exposure and LBW and PTB.
3.1.5. Publication bias
In PTB studies, visual inspection of the funnel plot in which each
study's effect size (as measured by log RR) was plotted against theEffect of moderator
eterogeneity
df
ithin
P value % Variance
explained
Qdf
between
P value % Variance
explained
7.98 .02 55 0.31 .57 1
8.45 .003 73
2.77 .08 45 0.21 .66 1
9.66 .003 69
0.11 .76 0 4.32 .12 12
5.87 .001 73
5.64 .23 29
5.81 .02 83 0.01 .85 0
7.812 .006 57
5.117 .006 52 0.41 .55 1
3.59 .14 33
4.212 .02 50 2.61 .11 5
8.114 .20 23
2.03 .57 0 11.52 .003 23
7.410 .07 43
8.212 .11 34
0.15 .07 50 0.11 .70 0
9.021 .01 46
us nondepressed, Q1=1.9, P=.17; mixed versus nondepressed, Q1=0.4, P=.51.
rsus nondepressed, Q1=4.4, P=.04; mixed versus nondepressed, Q1=2.1, P=.14.
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studies with negative ﬁndingsmay not have been published; evidence
of possible publication bias was conﬁrmed using the regression
intercept approach [45] (P=.001). As shown in Table 4, the trim-and-
ﬁll adjusted RRs for PTB, while generally lower than the unadjusted
RRs, are robust to the effects of publication bias. There was no
evidence of publication bias for LBW studies.
4. Discussion
This systematic review found that antidepressant exposure during
pregnancy was associated with signiﬁcant increased risks of LBW and
PTB. A prior meta-analysis by Lattimore (2005) in which nine studies
were included also examined this relationship and showed a
nonsigniﬁcant increase in risk for PTB (OR: 1.85, 95% CI: 0.79–4.29)
but a stronger association for an increase in risk for LBW (OR: 3.64,
95% CI: 1.01–13.08) [49]. One explanation for the differences found
between our study and the Lattimore study is that the inclusion
criteria used in each study differed (we included all studies with the
outcomes of interest — both prospective and retrospective — while
the Lattimore study included only prospective studies). A more recent
meta-analysis by Ross et al. that reviewed studies completed through
2010 also conﬁrmed the existence of a statistically signiﬁcant
relationship between antidepressant exposure in pregnancy and
both LBW and PTB [12]. However, Ross et al. emphasized that the
differences found between women exposed to antidepressants versus
those not exposed on gestational age (approximately 3 days shorter)
and birth weight (approximately 75 g lower) were small and of
questionable clinical signiﬁcance.
There is some evidence that the length of exposure or timing of
exposure during certain trimesters may inﬂuence antidepressants'
effects on fetal development and subsequent birth outcomes. An early
study by Chambers et al. found that late ﬂuoxetine exposure was
associated with PTB and LBW compared with earlier exposure [40].
Other work suggests that the timing of [27] or duration of [50]
antidepressant exposure inﬂuences the risk of these outcomes.
Findings from a recent study by Wisner et al. also suggested that the
timing of exposure may affect birth outcomes [27]. They found that
mothers taking an antidepressant throughout pregnancy were more
likely to have PTB infants than those exposed partially or not at all
during pregnancy. On the other hand, a study by Oberlander et al. that
used propensity scorematching on population-based data of pregnant
women showed that longer antidepressant exposure duration during
pregnancy and not timing of exposure was associated with LBW [50].
Antidepressant dosing has also been implicated as a factor in affecting
adverse birth outcomes. For instance, a recent study that examined
antidepressant dosing found that pregnant women exposed to high
doses of antidepressants were ﬁvefold more likely to have PTBs than
those who were exposed to low-medium doses [21].
These results must be tempered by results of a recent meta-
analysis that found that the illness of depression was also associated
with risk of LBW and PTB [2]. Moreover, Wisner et al. have shown that
both persistent depressive symptoms throughout pregnancy as well
as antidepressant exposure were independent risk factors for LBW
and PTB [27]. Tapering antidepressants in pregnant women with
histories of depression has also been shown to be associated with a
signiﬁcantly higher risk of relapse compared to women remaining on
antidepressant treatment [51]. Lack of depression treatment in
pregnancy increases the likelihood that depression will continue
into the postpartum period with attendant suffering of the mother
and possible complications in maternal–infant bonding, delayed
developmental milestones and subsequent behavioral problems [52].
The decision to initiate or remain on antidepressant treatment in
pregnant women should be based on risk-beneﬁt ratio and should
occur in the context of shared decision making between the patient
and her physician. It is certainly reasonable in many women, givenconcerns about both depression and SSRI use being linked to adverse
birth outcomes, to initiate treatment with an evidence-based
psychotherapy such as interpersonal therapy or cognitive behavioral
therapy and potentially adding an antidepressant for nonresponse.
However, the highest risk of depression during pregnancy is in low-
income populations, which often have the greatest barriers to ﬁnding
psychotherapeutic services due to limitations in insurance coverage
for mental health issues. There are also limitations in being able to pay
out-of-pocket costs since co-pays are generally higher for mental
health services. Lastly, low-income patients face a multitude of
difﬁculties in attending mental health visits including taking time off
from work, obtaining childcare services and transportation costs.
Strengths of this study include the development of a coding
sheet for inclusion and methodological quality a priori. We also
aimed to characterize the quality of studies based on their ability to
control important confounding factors such as the severity of
depression, smoking and alcohol use which all affect birth out-
comes. We were able to extend the ﬁndings of our colleagues Ross
et al. [12] by including eight additional studies that have been
published since 2011.
The main limitation of our study is exclusion of studies based on
our selection criteria. For instance, studies in which only the means of
birth weight or gestational age were provided were not included in
our study if authors did not reply to our request for additional data (14
studies were excluded). Furthermore, the included studies varied
widely in design, type of population, control group andmethods. Most
importantly, few studies were able to control for all potential
confounding factors that are associated with the exposure (antide-
pressant use) and events (PTB and LBW). Pregnant women with
depression have signiﬁcantly more pregnancy-related somatic symp-
toms [53], which likely lead tomore physician visits, aremore likely to
take over-the-counter and allopathic medicines for these somatic
symptoms, have more comorbid medical illnesses preceding preg-
nancy such as hypertension [54] and have higher rates of smoking,
higher body mass indices and use of illicit substances. Moreover,
women with greater depression severity and persistence of depres-
sion aremore likely to receive antidepressant treatment (confounding
by indication) and few studies controlled for severity or persistence of
depression. More prospective epidemiologic studies that control for
all these potential confounding factors as well as severity of
depression are needed to better describe the strength of association
between antenatal antidepressant exposure and PTB and LBW.
5. Conclusions
Antidepressant use during pregnancy signiﬁcantly increase the
risk for PTB and LBW. Our ﬁnding highlights the need for a careful
examination of the risk–beneﬁt ratio when considering the
initiation or maintenance of antidepressant therapy in pregnant
women with depression.
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